首页> 美国卫生研究院文献>Virology Journal >Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis
【2h】

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis

机译:恩替卡韦和阿德福韦在未经HBeAg阳性的亚洲慢性乙型肝炎患者中48周疗效的比较:一项荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAlthough entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic hepatitis B (CHB). The aim of this study was to evaluate the 48-week efficacy between the two drugs in HBeAg-positive nucleos(t)ide-naïve Asian CHB patients with the method of Meta analysis, which was generally accepted by the international as the best evidence for evaluating the efficacy of drugs.
机译:背景尽管恩替卡韦和阿德福韦在大多数亚洲国家被广泛使用,但从荟萃分析中得出的结论很少用于比较恩替卡韦和阿德福韦在未接受过核苷酸治疗的亚洲慢性乙型肝炎(CHB)患者中的疗效。这项研究的目的是通过Meta分析方法评估这两种药物在HBeAg阳性,未曾接受过治疗的亚洲CHB患者中的48周疗效,该方法已被国际公认的最佳证据。评估药物的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号